Daesung Microbiological Labs. Co. Ltd - Asset Resilience Ratio
Daesung Microbiological Labs. Co. Ltd (036480) has an Asset Resilience Ratio of 7.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 036480 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Daesung Microbiological Labs. Co. Ltd's Asset Resilience Ratio has changed over time. See 036480 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Daesung Microbiological Labs. Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Daesung Microbiological Labs. Co. Ltd (036480) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.43 Billion | 7.66% |
| Total Liquid Assets | ₩4.43 Billion | 7.66% |
Asset Resilience Insights
- Limited Liquidity: Daesung Microbiological Labs. Co. Ltd maintains only 7.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Daesung Microbiological Labs. Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Daesung Microbiological Labs. Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Daesung Microbiological Labs. Co. Ltd (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Daesung Microbiological Labs. Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.51% | ₩9.05 Billion ≈ $6.14 Million |
₩58.38 Billion ≈ $39.56 Million |
-2.73pp |
| 2023-12-31 | 18.24% | ₩11.73 Billion ≈ $7.95 Million |
₩64.29 Billion ≈ $43.57 Million |
-1.51pp |
| 2022-12-31 | 19.75% | ₩12.86 Billion ≈ $8.71 Million |
₩65.11 Billion ≈ $44.12 Million |
+3.88pp |
| 2021-12-31 | 15.86% | ₩9.93 Billion ≈ $6.73 Million |
₩62.62 Billion ≈ $42.44 Million |
-0.28pp |
| 2020-12-31 | 16.14% | ₩10.05 Billion ≈ $6.81 Million |
₩62.26 Billion ≈ $42.19 Million |
-8.49pp |
| 2019-12-31 | 24.63% | ₩12.50 Billion ≈ $8.47 Million |
₩50.77 Billion ≈ $34.40 Million |
-4.70pp |
| 2018-12-31 | 29.33% | ₩11.17 Billion ≈ $7.57 Million |
₩38.10 Billion ≈ $25.82 Million |
+2.98pp |
| 2017-12-31 | 26.35% | ₩9.17 Billion ≈ $6.21 Million |
₩34.78 Billion ≈ $23.57 Million |
-1.44pp |
| 2016-12-31 | 27.79% | ₩9.90 Billion ≈ $6.71 Million |
₩35.61 Billion ≈ $24.13 Million |
+22.98pp |
| 2015-12-31 | 4.82% | ₩1.56 Billion ≈ $1.06 Million |
₩32.42 Billion ≈ $21.97 Million |
+1.02pp |
| 2014-12-31 | 3.79% | ₩1.05 Billion ≈ $714.28K |
₩27.79 Billion ≈ $18.83 Million |
+0.37pp |
| 2013-12-31 | 3.42% | ₩990.00 Million ≈ $670.91K |
₩28.95 Billion ≈ $19.62 Million |
-0.74pp |
| 2012-12-31 | 4.16% | ₩1.06 Billion ≈ $719.02K |
₩25.49 Billion ≈ $17.28 Million |
-- |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more